vimarsana.com
Home
Live Updates
Tiziana Advances Phase 2 Site Selection For Its Lead Clinica
Tiziana Advances Phase 2 Site Selection For Its Lead Clinica
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update - Roche Holding (OTC:RHHBY), Sanofi (NASDAQ:SNY)
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Related Keywords
Italy ,
Milan ,
Lombardia ,
Tiziana Foralumab ,
Mathew Davis ,
Proceedings Of The National Academy Sciences ,
Tiziana Life Sciences Ltd Tlsarecently ,
Genentech ,
Provention Bio Inc ,
Nasal Administration ,
Tiziana Life Sciences Ltd ,
Secondary Progressive Multiple Sclerosis ,
National Academy ,
Provention Bio ,
Hoffmann La Roche ,
Jesse Orrico ,